Data:2009-12-12 2:34
Category: Money tips Release Date: 2006-10-18
Huadong Medicine (000,963 market, information, reviews, search) is mainly engaged in the production and sale of specialty pharmaceuticals, especially in the field of organ transplantation in China pharmaceutical companies have established a good market position. The company expects 2006 sales will reach 420 million yuan transplant drugs, an increase of 10%, of which Cyspin sales revenue of 2 billion yuan, 100 to make capsules of 2 billion, while new products, competitions can be flat at 2,000 million.
2006's transplant drug sales revenue growth slowed mainly due to anti-commercial bribery under the impact of new products, sales promotion blocked. But in the long run, the domestic drug market prospects for drugs throughout the transplant is very broad. There are about 150 million people every year in China end-stage organ failure due to the need for organ transplants, but only 1 million people a year access to transplantation for the treatment, mainly because of: lack of donor organs. Is expected that once brain death legislation introduced, this situation will improve. Transplant medicine is expected in 2007 revenue growth will exceed 10%. The company's largest shareholder China Grand Group in October 2006 of the share reform promised in the next two years, its subsidiaries into the listed company shares and does not spread there is equity amortization issues. Of calculating profits by 2005, these assets will increase the company's net profit of 4,400 million yuan.
KGI Securities analyst Xu Jun, and so that the company's current trading price is equivalent to 2006 earnings per share of 30 times and 25.1 times in 2007. Taking into account the main reason for the early repression stock price up down is clear, the asset injection will be substantive progress in 2007, the company a 12-month target price of 7.2 yuan, the first time to give an "overweight" recommendation.
